# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-045297
Filing Date
2024-04-18
Accepted
2024-04-18 06:06:44
Documents
4
Period of Report
2024-05-15

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | engene_2024_def14a.htm | DEF 14A | 1165489
2 | GRAPHIC | img18171159_0.jpg | GRAPHIC | 7709
3 | GRAPHIC | img18171159_1.jpg | GRAPHIC | 632272
4 | GRAPHIC | img18171159_2.jpg | GRAPHIC | 315416
| Complete submission text file | 0000950170-24-045297.txt |  | 2482621

Mailing Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1
Business Address 4868 RUE LEVY, SUITE 220 SAINT-LAURENT A8 H4R 2P1 (514) 332-4888
enGene Holdings Inc. (Filer) CIK: 0001980845 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: DEF 14A | Act: 34 | File No.: 001-41854 | Film No.: 24852725
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)